2,718 Shares in Glaukos Co. (NYSE:GKOS) Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC acquired a new position in Glaukos Co. (NYSE:GKOS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,718 shares of the medical instruments supplier’s stock, valued at approximately $216,000.

A number of other large investors also recently bought and sold shares of the business. National Bank of Canada FI acquired a new position in shares of Glaukos during the fourth quarter worth $46,000. GAMMA Investing LLC acquired a new position in shares of Glaukos during the fourth quarter worth $55,000. Quadrant Capital Group LLC increased its position in shares of Glaukos by 54.8% during the fourth quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock worth $74,000 after purchasing an additional 329 shares in the last quarter. Aigen Investment Management LP acquired a new position in shares of Glaukos during the fourth quarter worth $228,000. Finally, Xponance Inc. increased its position in shares of Glaukos by 4.1% during the fourth quarter. Xponance Inc. now owns 2,879 shares of the medical instruments supplier’s stock worth $229,000 after purchasing an additional 113 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. upped their price target on Glaukos from $108.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, May 2nd. StockNews.com lowered shares of Glaukos from a “hold” rating to a “sell” rating in a report on Tuesday, February 27th. Truist Financial reissued a “buy” rating and set a $125.00 price objective (up from $120.00) on shares of Glaukos in a report on Thursday, May 2nd. Citigroup boosted their price objective on shares of Glaukos from $120.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, May 22nd. Finally, Needham & Company LLC boosted their price objective on shares of Glaukos from $108.00 to $113.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $112.27.

Glaukos Trading Up 0.4 %

GKOS stock opened at $112.42 on Wednesday. The company’s 50-day simple moving average is $107.94 and its 200-day simple moving average is $95.18. The company has a quick ratio of 4.68, a current ratio of 5.38 and a debt-to-equity ratio of 0.78. Glaukos Co. has a 52-week low of $59.22 and a 52-week high of $116.25. The firm has a market cap of $5.66 billion, a P/E ratio of -39.03 and a beta of 1.09.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.12). Glaukos had a negative return on equity of 24.69% and a negative net margin of 43.15%. The firm had revenue of $85.60 million for the quarter, compared to analysts’ expectations of $79.60 million. During the same period in the previous year, the company earned ($0.59) earnings per share. The company’s revenue was up 15.8% compared to the same quarter last year. As a group, equities analysts forecast that Glaukos Co. will post -2.24 EPS for the current fiscal year.

Insider Transactions at Glaukos

In related news, COO Joseph E. Gilliam sold 2,500 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $113.50, for a total transaction of $283,750.00. Following the completion of the transaction, the chief operating officer now owns 101,845 shares in the company, valued at approximately $11,559,407.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CFO Alex R. Thurman sold 434 shares of the company’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $95.33, for a total transaction of $41,373.22. Following the completion of the transaction, the chief financial officer now owns 54,166 shares in the company, valued at approximately $5,163,644.78. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Joseph E. Gilliam sold 2,500 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $113.50, for a total transaction of $283,750.00. Following the transaction, the chief operating officer now owns 101,845 shares of the company’s stock, valued at approximately $11,559,407.50. The disclosure for this sale can be found here. Insiders have sold a total of 81,475 shares of company stock valued at $8,387,713 in the last ninety days. 6.40% of the stock is currently owned by corporate insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.